The patient complained of tingling in her lips.Calcium gluconate 8.5% at 12ml per hour was administered iv into the return line of the cellex procedural kit by the physician due to use of the anticoagulant, acda, in the treatment.During the treatment, the patient complained about tingling in her lips.The physician increased the administration of the calcium gluconate to 14ml per hour.No further adjustments of the calcium, gluconate were made.The patient was stable at the time of the event.No service order was generated.The product was not returned for evaluation.
|
A batch record review of lot c132 was conducted.There were no nonconformances associated with this lot.The lot met release requirements.Trends were reviewed for complaint category, other adverse event.In this case the other adverse event was tingling of the lips.There were no trends detected for this complaint category.No capa was initiated for this complaint category.Based on the medical assessment, the (b)(6) female with chronic gvhd developed tingling in her lips.The patient was on acda anticoagulant.The patient was administered calcium gluconate 8.5% at 12 ml per hour.This case is serious and related to ecp.The assessment is based on information available at the time of the investigation.No product was returned for investigation; therefore, it could not be determined if the product met specification based solely on the information provided by the customer.Complaints are monitored through tracking and trending.If a trend is detected, further investigation will be conducted through the capa/continuous improvement process.(b)(4).
|